Chat
Drug Screen 9 Panel, Serum or Plasma - Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation
Copy Utility
Monitor patient compliance.
Qualitative Enzyme-Linked Immunosorbent Assay/Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Sun-Sat
1-2 days
Confirmation: 1-4 days
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).
Remove plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 3 mL) Also acceptable: Serum.
Refrigerated.
Specimens exposed to repeated freeze/thaw cycles. Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Hemolyzed specimens.
Cocaine and cocaethylene are more stable in fluoride-preserved plasma than serum.
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years
| Drugs Covered and Cutoff Concentrations |
|
|---|---|
| Drugs/Drug Classes |
Screen |
| Amphetamines | Effective August 17, 2020 20 ng/mL |
| Methamphetamine | Effective August 17, 2020 20 ng/mL |
| Barbiturates | Effective August 17, 2020 50 ng/mL |
| Benzodiazepines | Effective August 17, 2020 50 ng/mL |
| Buprenorphine | 1 ng/mL |
| Cannabinoids | Effective August 17, 2020 20 ng/mL |
| Cocaine | Effective August 17, 2020 20 ng/mL |
| Methadone | Effective August 17, 2020 25 ng/mL |
| Opiates | Effective August 17, 2020 20 ng/mL |
| Oxycodone | Effective August 17, 2020 20 ng/mL |
| Phencyclidine | Effective August 17, 2020 10 ng/mL |
Drugs/Drug classes reported as "Positive" are automatically reflexed to mass spectrometry confirmation/quantitation. An unconfirmed positive immunoassay screen result may be useful for medical purposes but does not meet forensic standards. The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are automatically reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Laboratory Developed Test (LDT)
Screen-positive specimens are automatically confirmed by GC/MS and/or LC-MS/MS; additional charges may apply.
Hotline History
80307; if reflexed, add 80324; 80345; 80346; 80348; 80349; 80353; 80358; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480 )
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0092419 | Drug Screen Comments, Serum or Plasma | 48767-8 |
| 0092421 | Cannabinoids, S/P, Screen | 8172-9 |
| 0092422 | Cocaine, S/P, Screen | 8191-9 |
| 0092423 | Opiates, S/P, Screen | 8219-8 |
| 0092424 | Phencyclidine, S/P, Screen | 8236-2 |
| 0092425 | Amphetamines, S/P, Screen | 8149-7 |
| 0092426 | Barbiturates, S/P, Screen | 20421-4 |
| 0092427 | Benzodiazepines, S/P, Screen | 46976-7 |
| 0092428 | Methadone, S/P, Screen | 59705-4 |
| 0092430 | Oxycodone, S/P, Screen | 13576-4 |
| 0093414 | Methamphetamine, S/P, Screen | 3777-0 |
| 2013568 | Buprenorphine, S/P, Screen | 3413-2 |
- Pain Management
Feedback
